241302: POST-MARKETING non-interventional safety evaluation of obizur in the treatment of bleeding episodes for patients with acquired hemophilia A (241302: US Post-Marketing Safety Study)

First published 17/08/2020

Last updated 02/04/2024

EU PAS number:

EUPAS36659

Study

Finalised

Documents

Study protocol

Initial protocol

241302-protocol-original-redact

English (831.52 KB - PDF) View document

Updated protocol

241302-protocol-amendment-3-redact

First published: 22/02/2024

English (882.4 KB - PDF) View document

Study results

241302-clinical-study-report-redact

English (687.88 KB - PDF) View document

Study report

Other information

Secondary tabs